Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$20+ achievable here on the right set of news pieces
<<On Alert -- News Pending>> $PULM
Yes -- next PR we fly. That PR is imminent -- yet likely being advanced as far as it can behind the scenes before coming to the public -- as it will attract national attention. IMO
$PULM
Originally P2 Results for PUR1900 (Pulmazole) were suppose to be released about right now -- yet they got delayed b/c of the COVID-19 disrupting their testing facilities -- with their website now saying 1H-2021.
Although they likely have early/preliminary results (as it was running for 2-3 months or so at minimum). FDA Gave the Fast Track in January -- so obviously they had some data to share with them.
Then there is PUR1800 -- which should is effected by the same as above -- yet is with Johnson & Johnson so clearly there may be other applications in play/etc...
$PULM
Very exciting days coming; when news drop lots of new faces will show up.
$PULM
Moderna $MRNA Looking Good!
Moderna Folks -- may want to check out $PULM -- iSPERSE delivery platform (inahler via small cationic molecules) which works with any medicine/compound. Also founded by Robert Langer (who was a co-founder here at Moderna).
Maybe news soon... could be a collaboration b/w the two.
Just IMO.
Moderna & Pulmatrix both founded by Bob Langer in the MIT Labs. Moderna is looking for an inhaled version.
So is Gilead..
So are others..
$PULM
Potential to license iSPERSE with Gilead & Moderna....
$PULM
I don't believe so. P2 Results for Pulmazole w/ Cipla + P2 Results for PUR1800 w/ Johnson & Johnson + Strong Nasocalm pathway forward + news in between = $1-$2B market cap.
IMO only
Nice I have a very healthy position with cost average 1.89 (been here for quite a while) -- best position we have been in ever. Time to make the switch from theoretical to commercial. And in a big way too.
All IMO.
$PULM
$PULM PT1: $5, PT2: $10, PT3: $20+
News is imminent. Peer reviewed data on their new anti-contagion Nasocalm product + manufacturing news. + Perhaps some additional liscensing reviews.
Great add -- PT $5 upon the expected news release -- blastoff time.
$PULM
Nice -- better to be in the game than not at all -- been following this ticker for 2 years; very excited about the upcoming week(s).
$PULM
Nothing to do with current company, IMO -- this too shall pass. And higher we shall go.
$MSMY
The shares hitting the bid must still be from old toxic notes -- no other explanation really, imo.
$MSMY
$PULM Last Call -- $1.45
What is Nasocalm, our CV-19 Response, all about? This 2006 study shared yesterday by @Spudman7 shows us.
<<Exhaled Bio-aerosols were 72% suppressed over 6 hours>>
Authors David Edwards (Founder of Sensory-Cloud and previous Pulmatrix alumni) & Robert Clarke (previous 10 year CEO + consultant for Pulmatrix).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108402/
$PULM
good morning -- coffee just finished brewing
What is Nasocalm, our CV-19 Response, all about? This 2006 study shared yesterday by @Spudman7 shows us.
<<Exhaled Bio-aerosols were 72% suppressed over 6 hours>>
Authors David Edwards (Founder of Sensory-Cloud and previous Pulmatrix alumni) & Robert Clarke (previous 10 year CEO + consultant for Pulmatrix).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108402/
$PULM
I put in a request to change the board to "US OTC Wholesale Distributor" boards instead of Media Conglomerate. Other categories didn't seem right, as we don't do cannabis (and they don't have the option for CBD).
$MSMY
yes -- waiting on PR(s) -- have to think they are getting their ducks in a row -- not b/c they have a lack of things to say.
IMO
$PULM
Hmm..... Manhattan Project....?
https://www.zerohedge.com/health/secret-covid-19-manhattan-project-led-billionaires-seeks-gain-trump-admins-ear
The until now secretive group is led by a 33-year-old physician-turned-venture capitalist, Tom Cahill, and is described as an elite go-between the pharmaceutical industry and Trump administration decision-makers, or an "ad hoc review board" of sorts pursuing cutting edge outside the box ideas.
The scientists include a dozen world renowned researchers, pathology experts and inventors closely networked at institutions ranging from The Scripps Research Lab in La Jolla, California, to Yale University School of Medicine to Harvard to MIT's Laboratory for Nuclear Security and Policy to private companies and labs like Merck and others.
Recommendations and ideas floated by Scientists to Stop Covid-19 have already reportedly had far-reaching influence, including affecting policy inside FDA and the Department of Veterans Affairs, and the group is reportedly advising close Pence aide Nick Ayers.
Good callout
Good things coming for $PULM
$PULM Current Partners:
Cipla:
2nd Largest generics company in India -- 65% Respitatory Share in India -- $5B Pulmazole Market with clear path towards commercialization + FDA fast track.
J&J:
Largest Pharma Company in the world -- $100M cash via PUR1800 liscensing + opens the door for application to their portfolio of products
Sensory Cloud:
COVID-19 therapeutics response, former Pulmatrix founder David Edwards involved; David Langer endorsement on his COVID-19 zoom webinar; Previous P1 trial/DARPA funding in 2010; Worldwide royalties
Nocion Therapeutics:
Former Pulmatrix alumni Ricky Batycyk; exploratory research collaboration for new innovation ideas
MIT/Harvard Engineering Labs:
Academia created product which is now iSPERSE -- by some of the brightest people in the world -- with the purposes of bio-defense.
$PULM Current Partners
Cipla:
2nd Largest generics company in India -- 65% Respitatory Share in India -- $5B Pulmazole Market with clear path towards commercialization + FDA fast track.
J&J:
Largest Pharma Company in the world -- $100M cash via PUR1800 liscensing + opens the door for application to their portfolio of products
Sensory Cloud:
COVID-19 therapeutics response, former Pulmatrix founder David Edwards involved; David Langer endorsement on his COVID-19 zoom webinar; Previous P1 trial/DARPA funding in 2010; Worldwide royalties
Nocion Therapeutics:
Former Pulmatrix alumni Ricky Batycyk; exploratory research collaboration for new innovation ideas
MIT/Harvard Engineering Labs:
Academia created product which is now iSPERSE -- by some of the brightest people in the world -- with the purposes of bio-defense.
$PULM Current Partners:
Cipla:
2nd Largest generics company in India -- 65% Respitatory Share in India -- $5B Pulmazole Market with clear path towards commercialization + FDA fast track.
J&J:
Largest Pharma Company in the world -- $100M cash via PUR1800 liscensing + opens the door for application to their portfolio of products
Sensory Cloud:
COVID-19 therapeutics response, former Pulmatrix founder David Edwards involved; David Langer endorsement on his COVID-19 zoom webinar; Previous P1 trial/DARPA funding in 2010; Worldwide royalties
Nocion Therapeutics:
Former Pulmatrix alumni Ricky Batycyk; exploratory research collaboration for new innovation ideas
MIT/Harvard Engineering Labs:
Academia created product which is now iSPERSE -- by some of the brightest people in the world -- with the purposes of bio-defense.
good to see you -- hope you join this ride a bit -- i think we may see this on the national stage -- TRUMP mention NasoCalm & Pulmatrix in the near future? J&J Partnership involvement? MIT Labs.
Their primary product line ain't bad either ;)
Hype train incoming -- legendary returns possible over the next few weeks+
$PULM
$PULM $1.40 -- Here we gooo!
Wondering if J&J (Janssen) may be involved in their COVID-19 response -- perhaps manufacturing?
Seeing news on their COVID-19 anti-contagion product which sparks a big run higher.
I see the path towards such.. imo.
Probably weeks...
Indeed
Product Review: The product packaging design on the 2OZ Hand Sanitizer is amazing. Far superior to the 2OZ regular ones I have bought before at a CVS/Walgreens.
The nozzle allows for portion control really nicely.
$MSMY
$PULM - $10+++ coming upon peer-reviewed data.
Unbelievably huge endorsement / news. Market doesn't understand yet.